Rocky Mountain Spotted Fever Medication
- Author: Burke A Cunha, MD; Chief Editor: Michael Stuart Bronze, MD more...
Medication Summary
In adults with Rocky Mountain spotted fever (RMSF), the drug of choice is doxycycline. Chloramphenicol is an alternative, although doxycycline is preferable because tetracyclines have been shown to be associated with a higher survival rate than chloramphenicol.[18] In vitro and in ovo R rickettsii are also susceptible to rifampin.
Doxycycline therapy also treats Lyme disease, ehrlichiosis, and relapsing fever—entities often clinically confused with RMSF.[19] Oral formulations may be used for patients being treated at home or for hospitalized patients who are not vomiting or obtunded.
Doxycycline is relatively contraindicated in early pregnancy due to its involvement in fetal teeth and bone development and hepatotoxicity.
In 1997, the American Academy of Pediatrics revised treatment options for children with RMSF. Doxycycline became the preferred drug choice for treating children of any age because of the potential for severe or fatal cases.
Short courses of doxycycline to treat RMSF do not cause significant dental staining.[20] Beta-lactam antibiotic coverage does not treat RMSF. Some new quinolones have antirickettsial effects in vitro, but the clinical experience in RMSF is limited.
Topical cycloplegics, such as cyclopentolate 1% (1 gtt bid/tid), reduce discomfort from uveitis. Topical ophthalmic steroids, such as prednisolone acetate 1% (1 drop bid/tid/qid), reduce ocular inflammation. Artificial tears and lubricating ointment may be used as needed or frequently, depending on the amount of discomfort.
Antibiotics
Class Summary
Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.
Doxycycline (Adoxa, Oraxyl , Doryx, Vibramycin)
Doxycycline is the drug of choice for Rocky Mountain spotted fever (RMSF). It inhibits protein synthesis and, consequently, bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.
Chloramphenicol
Chloramphenicol is the alternative choice for RMSF in pregnant women and patients allergic to tetracyclines. It binds to 50S bacterial ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis.
Anticholinergic agents, Ophthamic
Class Summary
These agents relax any ciliary muscle spasm that can cause a deep, aching pain and photophobia. Cycloplegic agents are also mydriatics, and the practitioner should make sure that the patient does not have glaucoma. This medication could provoke an acute angle-closure attack.
Cyclopentolate 1% (AK-Pentolate, Cyclogyl, Cylate)
Cyclopentolate is the drug of choice in corneal abrasions. It blocks the muscle of the ciliary body and the sphincter muscle of the iris from responding to cholinergic stimulation, thus causing mydriasis and cycloplegia. Cyclopentolate induces mydriasis in 30-60 minutes and cycloplegia in 25-75 minutes. These effects last up to 24 hours.
Topical Corticosteroids
Class Summary
Corticosteroids suppress active disease, which is assumed to be due to inflammatory mechanisms.
Prednisolone ophthalmic (Omnipred, Pred Forte, Pred Mild)
This agent decreases autoimmune reactions, possibly by suppressing key components of the immune system.
Loteprednol etabonate (Lotemax, Alrex)
Loteprednol etabonate decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability. It is a topical ester steroid drop with decreased risk of glaucoma. Loteprednol etabonate is available in 0.2% and 0.5% drops.
Nonsteroidal Anti-Inflammatory Agents
Class Summary
These drugs have analgesic and anti-inflammatory activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.
Diclofenac ophthalmic (Voltaren Ophthalmic)
This agent inhibits prostaglandin synthesis by decreasing the activity of the enzyme cyclooxygenase, which in turn decreases formation of prostaglandin precursors. Diclofenac ophthalmic may facilitate outflow of aqueous humor and decreases vascular permeability.
Ketorolac ophthalmic (Acular, Acuvail)
Ketorolac ophthalmic is available in preserved bottles, as well as in preservative-free, single-dose-unit containers.
Sexton DJ, Corey GR. Rocky Mountain "spotless" and "almost spotless" fever: a wolf in sheep's clothing. Clin Infect Dis. Sep 1992;15(3):439-48. [Medline].
Salgo MP, Telzak EE, Currie B, et al. A focus of Rocky Mountain spotted fever within New York City. N Engl J Med. May 26 1988;318(21):1345-8. [Medline].
Openshaw JJ, Swerdlow DL, Krebs JW, et al. Rocky mountain spotted fever in the United States, 2000-2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg. Jul 2010;83(1):174-82. [Medline]. [Full Text].
Stromdahl EY, Jiang J, Vince M, Richards AL. Infrequency of Rickettsia rickettsii in Dermacentor variabilis removed from humans, with comments on the role of other human-biting ticks associated with spotted fever group Rickettsiae in the United States. Vector Borne Zoonotic Dis. Jul 2011;11(7):969-77. [Medline].
Marshall GS, Stout GG, Jacobs RF, et al. Antibodies reactive to Rickettsia rickettsii among children living in the southeast and south central regions of the United States. Arch Pediatr Adolesc Med. May 2003;157(5):443-8. [Medline].
Zavala-Castro JE, Dzul-Rosado KR, León JJ, Walker DH, Zavala-Velázquez JE. An increase in human cases of spotted fever rickettsiosis in Yucatan, Mexico, involving children. Am J Trop Med Hyg. Dec 2008;79(6):907-10. [Medline].
Demma LJ, Holman RC, Mikosz CA, et al. Rocky mountain spotted fever hospitalizations among American Indians. Am J Trop Med Hyg. Sep 2006;75(3):537-41. [Medline].
Holman RC, McQuiston JH, Haberling DL, Cheek JE. Increasing incidence of Rocky Mountain spotted fever among the American Indian population in the United States. Am J Trop Med Hyg. Apr 2009;80(4):601-5. [Medline].
Kirkland KB, Wilkinson WE, Sexton DJ. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis. May 1995;20(5):1118-21. [Medline].
Archibald LK, Sexton DJ. Long-term sequelae of Rocky Mountain spotted fever. Clin Infect Dis. May 1995;20(5):1122-5. [Medline].
Chen LF, Sexton DJ. What's new in Rocky Mountain spotted fever?. Infect Dis Clin North Am. Sep 2008;22(3):415-32, vii-viii. [Medline].
Sexton DJ, Gallis HA, McRae JR, Cate TR. Letter: Possible needle-associated Rocky Mountain spotted fever. N Engl J Med. Mar 20 1975;292(12):645. [Medline].
Buckingham SC, Marshall GS, Schutze GE, et al. Clinical and laboratory features, hospital course, and outcome of Rocky Mountain spotted fever in children. J Pediatr. Feb 2007;150(2):180-4, 184.e1. [Medline].
Byrd RP Jr, Vasquez J, Roy TM. Respiratory manifestations of tick-borne diseases in the Southeastern United States. South Med J. Jan 1997;90(1):1-4. [Medline].
Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. Mar 31 2006;55:1-27. [Medline].
Procop GW, Burchette JL Jr, Howell DN, Sexton DJ. Immunoperoxidase and immunofluorescent staining of Rickettsia rickettsii in skin biopsies. A comparative study. Arch Pathol Lab Med. Aug 1997;121(8):894-9. [Medline].
Markley KC, Levine AB, Chan Y. Rocky Mountain spotted fever in pregnancy. Obstet Gynecol. May 1998;91(5 Pt 2):860. [Medline].
Holman RC, Paddock CD, Curns AT, Krebs JW, McQuiston JH, Childs JE. Analysis of risk factors for fatal Rocky Mountain Spotted Fever: evidence for superiority of tetracyclines for therapy. J Infect Dis. Dec 1 2001;184(11):1437-44. [Medline].
Minniear TD, Buckingham SC. Managing Rocky Mountain spotted fever. Expert Rev Anti Infect Ther. Nov 2009;7(9):1131-7. [Medline].
Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J. May 1998;17(5):429-31. [Medline].

